{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:13:37Z","timestamp":1792397617729,"version":"4.4.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070213"],"award-info":[{"award-number":["82070213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor-T cell therapy, a groundbreaking cancer treatment, has achieved remarkable success against hematologic malignancies. However, CAR-T monotherapy faces challenges in certain cases, including treatment tolerance and relapse rates. To overcome these challenges, researchers are investigating combining CAR-T cells with other treatments to enhance therapeutic efficacy. Therefore, this review aims to investigate the progress of research in combining CAR-T cells for hematologic malignancies. It covers the basic principles and clinical applications of CAR-T cell therapy, detailing combinations with chemotherapy, immune checkpoint inhibitors, targeted drugs, radiotherapy, hematopoietic stem cell transplantation, and other treatments. These combinations synergistically enhance the antitumor effects of CAR-T cells and comprehensively target tumors through different mechanisms, improving patient response and survival rates.<\/jats:p>","DOI":"10.1186\/s40164-024-00536-0","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T08:01:40Z","timestamp":1721289700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["CAR-T cell combination therapies in hematologic malignancies"],"prefix":"10.1186","volume":"13","author":[{"given":"Delian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"536_CR1","doi-asserted-by":"crossref","unstructured":"Levin A, Shah NN. Chimeric antigen receptor modified T cell therapy in B cell non-hodgkin lymphomas. Am J Hematol. 2019; 94(S1).","DOI":"10.1002\/ajh.25403"},{"issue":"1","key":"536_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1146\/annurev-pharmtox-031720-102211","volume":"61","author":"EZ Song","year":"2021","unstructured":"Song EZ, Milone MC. Pharmacology of chimeric Antigen receptor\u2013modified T cells. Annu Rev Pharmacol Toxicol. 2021;61(1):805\u201329.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"536_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The Basic principles of chimeric Antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"27","key":"536_CR4","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene Ciloleucel in the Non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095\u2013106.","journal-title":"J Clin Oncol"},{"issue":"8","key":"536_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419\u201331.","journal-title":"Nat Med"},{"issue":"1","key":"536_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Experimental Hematol Oncol. 2023;12(1):14.","journal-title":"Experimental Hematol Oncol"},{"issue":"10","key":"536_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"26","key":"536_CR8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"8","key":"536_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson D, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"9","key":"536_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, et al. Three-year update of Tisagenlecleucel in Pediatric and Young Adult patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2023;41(9):1664\u20139.","journal-title":"J Clin Oncol"},{"issue":"26","key":"536_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"536_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"10254","key":"536_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"5","key":"536_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"536_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal R, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103.","journal-title":"Lancet Oncol"},{"issue":"7","key":"536_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ. Five-year outcomes for refractory B-Cell lymphomas with CAR T-Cell therapy. N Engl J Med. 2021;384(7):673\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"536_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, et al. Three-year Follow-Up of KTE-X19 in patients with Relapsed\/Refractory Mantle Cell Lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555\u201367.","journal-title":"J Clin Oncol"},{"issue":"5","key":"536_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Wang X, Sauter C, et al. Long-term follow-up of CD19 CAR therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"issue":"27","key":"536_CR19","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care Axicabtagene Ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"12","key":"536_CR20","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395.","journal-title":"Cancer Discov"},{"key":"536_CR21","doi-asserted-by":"publisher","first-page":"1165870","DOI":"10.3389\/fimmu.2023.1165870","volume":"14","author":"C Aparicio-P\u00e9rez","year":"2023","unstructured":"Aparicio-P\u00e9rez C, Carmona M, Benabdellah K, et al. Failure of ALL recognition by CAR T cells: a review of CD19-negative relapses after anti-CD19 CAR-T treatment in B-ALL. Front Immunol. 2023;14:1165870.","journal-title":"Front Immunol"},{"issue":"10","key":"536_CR22","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor Antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"20","key":"536_CR23","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u201310.","journal-title":"Blood"},{"issue":"2","key":"536_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/bjh.13562","volume":"171","author":"AG Evans","year":"2015","unstructured":"Evans AG, Rothberg PG, Burack WR, et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol. 2015;171(2):205\u20139.","journal-title":"Br J Haematol"},{"issue":"4","key":"536_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","volume":"31","author":"RG Majzner","year":"2017","unstructured":"Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution for the treatment of Childhood Cancers. Cancer Cell. 2017;31(4):476\u201385.","journal-title":"Cancer Cell"},{"issue":"399","key":"536_CR26","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.","journal-title":"Sci Transl Med"},{"issue":"16","key":"536_CR27","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Aplenc R, Teachey DT, et al. Chimeric Antigen receptor\u2013modified T cells for Acute Lymphoid Leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"536_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"536_CR29","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20136.","journal-title":"Nat Med"},{"issue":"22","key":"536_CR30","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to Express an Anti\u2013B-Cell maturation Antigen chimeric Antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267\u201380.","journal-title":"J Clin Oncol"},{"issue":"6","key":"536_CR31","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210\u201321.","journal-title":"J Clin Invest"},{"issue":"9","key":"536_CR32","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"7734","key":"536_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-018-0756-0","volume":"564","author":"X Meng","year":"2018","unstructured":"Meng X, Liu X, Guo X, et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature. 2018;564(7734):130\u20135.","journal-title":"Nature"},{"issue":"9","key":"536_CR34","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415\u201322.","journal-title":"Nat Immunol"},{"issue":"10","key":"536_CR35","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56(10):2388\u2013407.","journal-title":"Immunity"},{"issue":"3","key":"536_CR36","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.ymthe.2021.12.013","volume":"30","author":"S Huang","year":"2022","unstructured":"Huang S, Liu D, Sun J, et al. Tim-3 regulates sepsis-induced immunosuppression by inhibiting the NF-\u03baB signaling pathway in CD4 T cells. Mol Ther. 2022;30(3):1227\u201338.","journal-title":"Mol Ther"},{"issue":"8","key":"536_CR37","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen\u2013specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537\u201344.","journal-title":"Blood"},{"issue":"4","key":"536_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV, et al. Immune Inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote Tumoral Immune escape. Cancer Res. 2012;72(4):917\u201327.","journal-title":"Cancer Res"},{"issue":"5","key":"536_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"3","key":"536_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.","journal-title":"Cancer Cell"},{"key":"536_CR41","doi-asserted-by":"crossref","unstructured":"Riaz N, Havel JJ, Makarov V et al. Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell. 2017;171(4):934\u201349.","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"536_CR42","doi-asserted-by":"crossref","unstructured":"Allen GM, Frankel NW, Reddy NR et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022; 378(6625).","DOI":"10.1126\/science.aba1624"},{"issue":"3","key":"536_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"536_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2021011597","volume":"139","author":"CR Funk","year":"2022","unstructured":"Funk CR, Wang S, Chen KZ, et al. PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139(4):523\u201337.","journal-title":"Blood"},{"issue":"10","key":"536_CR45","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","volume":"12","author":"YG Lee","year":"2022","unstructured":"Lee YG, Guruprasad P, Ghilardi G, et al. Modulation of BCL-2 in both T Cells and Tumor Cells to enhance chimeric Antigen receptor T-cell immunotherapy against Cancer. Cancer Discov. 2022;12(10):2372\u201391.","journal-title":"Cancer Discov"},{"issue":"19","key":"536_CR46","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585\u201397.","journal-title":"Blood"},{"issue":"1","key":"536_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X Wang","year":"2018","unstructured":"Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric Antigen receptor\u2013redirected T cells against multiple myeloma. Clin Cancer Res. 2018;24(1):106\u201319.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"536_CR48","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s13402-023-00833-6","volume":"46","author":"Z Jin","year":"2023","unstructured":"Jin Z, Xiang R, Qing K, et al. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma. Cell Oncol. 2023;46(4):1143\u201357.","journal-title":"Cell Oncol"},{"issue":"12","key":"536_CR49","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","volume":"18","author":"M Works","year":"2019","unstructured":"Works M, Soni N, Hauskins C, et al. Anti\u2013B-cell maturation Antigen chimeric Antigen receptor T cell function against multiple myeloma is enhanced in the Presence of Lenalidomide. Mol Cancer Ther. 2019;18(12):2246\u201357.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"536_CR50","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","volume":"6","author":"S Gill","year":"2022","unstructured":"Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774\u201385.","journal-title":"Blood Adv"},{"issue":"19","key":"536_CR51","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650\u201360.","journal-title":"Blood"},{"issue":"6","key":"536_CR52","doi-asserted-by":"publisher","first-page":"298","DOI":"10.21037\/atm-22-20","volume":"10","author":"N Ping","year":"2022","unstructured":"Ping N, Qu C, Li M, et al. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory\/relapsed diffuse large B-cell lymphoma. Annals Translational Med. 2022;10(6):298.","journal-title":"Annals Translational Med"},{"key":"536_CR53","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lu W, Sun R, et al. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination with Nivolumab are safe and effective against Relapsed\/Refractory B-Cell non-hodgkin Lymphoma. Front Oncol. 2019;9:767.","journal-title":"Front Oncol"},{"key":"536_CR54","doi-asserted-by":"crossref","unstructured":"Xin X, Zhu X, Yang Y et al. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed\/refractory B-cell non-hodgkin-lymphoma. Cell Oncol. 2024.","DOI":"10.1007\/s13402-024-00940-y"},{"issue":"5","key":"536_CR55","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","volume":"116","author":"O Saifi","year":"2023","unstructured":"Saifi O, Breen WG, Lester SC, et al. Don\u2019t put the CART before the horse: the role of Radiation Therapy in Peri-CAR T-cell therapy for aggressive B-cell Non-hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2023;116(5):999\u20131007.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"536_CR56","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, Jain MD, Figura NB, et al. Radiation Therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-Cell lymphoma. Int J Radiat Oncol Biol Phys. 2019;105(5):1012\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"536_CR57","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","volume":"27","author":"SH Manjunath","year":"2021","unstructured":"Manjunath SH, Cohen AD, Lacey SF, et al. The safety of bridging Radiation with Anti-BCMA CAR T-Cell therapy for multiple myeloma. Clin Cancer Res. 2021;27(23):6580\u201390.","journal-title":"Clin Cancer Res"},{"key":"536_CR58","doi-asserted-by":"crossref","unstructured":"Cao Y, Xiao Y, Wang N et al. CD19\/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed\/Refractory Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy. 2021; 27(11): 910.e1-910.e11.","DOI":"10.1016\/j.jtct.2021.08.012"},{"issue":"5","key":"536_CR59","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1002\/ctm2.176","volume":"10","author":"J Wei","year":"2020","unstructured":"Wei J, Mao Z, Wang N, et al. Long-term outcomes of relapsed\/refractory double-hit lymphoma (r\/r DHL) treated with CD19\/22 CAR T-cell cocktail therapy. Clin Translational Med. 2020;10(5):e176.","journal-title":"Clin Translational Med"},{"key":"536_CR60","doi-asserted-by":"crossref","unstructured":"Xue F, Zheng P, Liu R et al. The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed\/Refractory Central Nervous System B-Cell Lymphoma. Journal of Oncology. 2022; 2022:2900310.","DOI":"10.1155\/2022\/2900310"},{"issue":"1","key":"536_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","volume":"7","author":"J Wei","year":"2022","unstructured":"Wei J, Xiao M, Mao Z, et al. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Therapy. 2022;7(1):101.","journal-title":"Signal Transduct Target Therapy"},{"issue":"8","key":"536_CR62","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, et al. Mechanisms of resistance to Noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022;386(8):735\u201343.","journal-title":"N Engl J Med"},{"key":"536_CR63","doi-asserted-by":"crossref","unstructured":"Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci. 2010;107(29):13075\u201380.","DOI":"10.1073\/pnas.1004594107"},{"issue":"1","key":"536_CR64","first-page":"62","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142(1):62\u201372.","journal-title":"Blood"},{"issue":"4","key":"536_CR65","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332.","journal-title":"N Engl J Med"},{"issue":"8","key":"536_CR66","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031\u201343.","journal-title":"Lancet Oncol"},{"issue":"1","key":"536_CR67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(1):21.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"536_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown R, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"10277","key":"536_CR69","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901.","journal-title":"Lancet"},{"issue":"9","key":"536_CR70","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117\u201327.","journal-title":"Blood"},{"issue":"8","key":"536_CR71","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052\u201364.","journal-title":"J Clin Invest"},{"key":"536_CR72","doi-asserted-by":"crossref","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. 2013; 122(15):2539\u201349.","DOI":"10.1182\/blood-2013-06-507947"},{"issue":"8","key":"536_CR73","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","volume":"76","author":"A Stiff","year":"2016","unstructured":"Stiff A, Trikha P, Wesolowski R, et al. Myeloid-derived suppressor cells Express Bruton\u2019s tyrosine kinase and can be depleted in Tumor-Bearing hosts by Ibrutinib Treatment. Cancer Res. 2016;76(8):2125\u201336.","journal-title":"Cancer Res"},{"issue":"2","key":"536_CR74","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ijc.33212","volume":"148","author":"F Fan","year":"2021","unstructured":"Fan F, Yoo HJ, Stock S, et al. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Int J Cancer. 2021;148(2):419\u201328.","journal-title":"Int J Cancer"},{"issue":"7","key":"536_CR75","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jcyt.2023.03.005","volume":"25","author":"W Luo","year":"2023","unstructured":"Luo W, Li C, Wu J, et al. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma. Cytotherapy. 2023;25(7):739\u201349.","journal-title":"Cytotherapy"},{"issue":"11","key":"536_CR76","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","volume":"22","author":"M Ruella","year":"2016","unstructured":"Ruella M, Kenderian SS, Shestova O, et al. The addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) improves responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016;22(11):2684\u201396.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"536_CR77","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","volume":"43","author":"JS Qin","year":"2020","unstructured":"Qin JS, Johnstone TG, Baturevych A, et al. Antitumor Potency of an Anti-CD19 chimeric Antigen receptor T-Cell therapy, Lisocabtagene Maraleucel in Combination with Ibrutinib or Acalabrutinib. J Immunother. 2020;43(4):107\u201320.","journal-title":"J Immunother"},{"issue":"1","key":"536_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-024-00484-9","volume":"13","author":"F Yan","year":"2024","unstructured":"Yan F, Jiang V, Jordan A, et al. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. Exp Hematol Oncol. 2024;13(1):14.","journal-title":"Exp Hematol Oncol"},{"issue":"15","key":"536_CR79","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1158\/0008-5472.CAN-16-1925","volume":"77","author":"R Abu Eid","year":"2017","unstructured":"Abu Eid R, Ahmad S, Lin Y, et al. Enhanced therapeutic efficacy and memory of Tumor-Specific CD8 T cells by Ex vivo PI3K-\u03b4 inhibition. Cancer Res. 2017;77(15):4135\u201345.","journal-title":"Cancer Res"},{"issue":"5","key":"536_CR80","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"W Zheng","year":"2018","unstructured":"Zheng W, O\u2019Hear CE, Alli R, et al. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia. 2018;32(5):1157\u201367.","journal-title":"Leukemia"},{"issue":"7","key":"536_CR81","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"AR Delbridge","year":"2015","unstructured":"Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22(7):1071\u201380.","journal-title":"Cell Death Differ"},{"issue":"3","key":"536_CR82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1054\/drup.2000.0142","volume":"3","author":"N Fujita","year":"2000","unstructured":"Fujita N, Tsuruo T. In vivo veritas: Bcl-2 and Bcl-XL mediate tumor cell resistance to chemotherapy. Drug Resist Updat. 2000;3(3):149\u201354.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"536_CR83","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","volume":"12","author":"DJ Goff","year":"2013","unstructured":"Goff DJ, Recart C, Sadarangani A, et al. A Pan-BCL2 inhibitor renders bone-marrow-Resident Human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013;12(3):316\u201328.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"536_CR84","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ccr.2004.07.011","volume":"6","author":"A Letai","year":"2004","unstructured":"Letai A, Sorcinelli MD, Beard C, et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004;6(3):241\u20139.","journal-title":"Cancer Cell"},{"issue":"3","key":"536_CR85","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/ptr.5766","volume":"31","author":"J Lee","year":"2017","unstructured":"Lee J, Sohn EJ, Yoon SW, et al. Anti-metastatic effect of Dehydrocorydaline on H1299 Non-small Cell Lung Carcinoma cells via inhibition of Matrix metalloproteinases and B Cell Lymphoma 2: Antimetastatic Effect of Dehydrocorydaline on H1299 cells. Phytother Res. 2017;31(3):441\u20138.","journal-title":"Phytother Res"},{"issue":"2","key":"536_CR86","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"AR Delbridge","year":"2016","unstructured":"Delbridge AR, Grabow S, Strasser A, et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99\u2013109.","journal-title":"Nat Rev Cancer"},{"issue":"25","key":"536_CR87","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","volume":"30","author":"MS Davids","year":"2012","unstructured":"Davids MS, Letai A. Targeting the B-Cell Lymphoma\/Leukemia 2 family in Cancer. J Clin Oncol. 2012;30(25):3127\u201335.","journal-title":"J Clin Oncol"},{"issue":"1","key":"536_CR88","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"12","key":"536_CR89","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859\u201366.","journal-title":"Nat Med"},{"issue":"3","key":"536_CR90","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/79802","volume":"1","author":"G Yu","year":"2000","unstructured":"Yu G, Boone T, Delaney J, et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000;1(3):2526.","journal-title":"Nat Immunol"},{"issue":"9","key":"536_CR91","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1016\/j.it.2018.07.002","volume":"39","author":"E Meinl","year":"2018","unstructured":"Meinl E, Thaler FS, Lichtenthaler SF. Shedding of BAFF\/APRIL receptors controls B cells. Trends Immunol. 2018;39(9):6736.","journal-title":"Trends Immunol"},{"issue":"3","key":"536_CR92","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","volume":"17","author":"P Schneider","year":"2005","unstructured":"Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17(3):282\u20139.","journal-title":"Curr Opin Immunol"},{"key":"536_CR93","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH, et al. \u03b3-secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6:7333.","journal-title":"Nat Commun"},{"issue":"1","key":"536_CR94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","volume":"369","author":"X Yuan","year":"2015","unstructured":"Yuan X, Wu H, Xu H, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369(1):20\u20137.","journal-title":"Cancer Lett"},{"issue":"2","key":"536_CR95","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422\u20139.","journal-title":"Nat Med"},{"key":"536_CR96","doi-asserted-by":"publisher","first-page":"599493","DOI":"10.3389\/fimmu.2021.599493","volume":"12","author":"C Li","year":"2021","unstructured":"Li C, Sun Y, Wang J, et al. PiggyBac-Generated CAR19-T cells plus Lenalidomide cause durable complete remission of triple-hit Refractory\/Relapsed DLBCL: a Case Report. Front Immunol. 2021;12:599493.","journal-title":"Front Immunol"},{"key":"536_CR97","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and Cancer. Annu Rev Immunol. 2019;37:457\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"536_CR98","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri.2016.80","volume":"16","author":"DE Speiser","year":"2016","unstructured":"Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599\u2013611.","journal-title":"Nat Rev Immunol"},{"key":"536_CR99","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ctrv.2017.01.009","volume":"54","author":"CY Ok","year":"2017","unstructured":"Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev. 2017;54:99\u2013109.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"536_CR100","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341.","journal-title":"Blood"},{"issue":"2","key":"536_CR101","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV, Kimble EL, Wright JH, et al. Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2024;8(2):453\u201367.","journal-title":"Blood Adv"},{"key":"536_CR102","doi-asserted-by":"publisher","first-page":"110092","DOI":"10.1016\/j.intimp.2023.110092","volume":"118","author":"L Lu","year":"2023","unstructured":"Lu L, Risch E, Halaban R, et al. Dynamic changes of circulating soluble PD-1\/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. Int Immunopharmacol. 2023;118:110092.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"536_CR103","doi-asserted-by":"publisher","first-page":"19712","DOI":"10.1038\/s41598-021-99311-y","volume":"11","author":"SY Oh","year":"2021","unstructured":"Oh SY, Kim S, Keam B, et al. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021;11(1):19712.","journal-title":"Sci Rep"},{"issue":"2","key":"536_CR104","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.13624","volume":"169","author":"L Chen","year":"2023","unstructured":"Chen L, Liu S, Adah D, et al. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma. Immunology. 2023;169(2):204\u201318.","journal-title":"Immunology"},{"issue":"1","key":"536_CR105","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Cheng C, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017;27(1):154\u20137.","journal-title":"Cell Res"},{"issue":"1","key":"536_CR106","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.","journal-title":"Sci Rep"},{"issue":"3","key":"536_CR107","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","volume":"68","author":"W Hu","year":"2019","unstructured":"Hu W, Zi Z, Jin Y, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunotherapy. 2019;68(3):365\u201377.","journal-title":"Cancer Immunol Immunotherapy"},{"issue":"1","key":"536_CR108","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.","journal-title":"J Hematol Oncol"},{"issue":"30","key":"536_CR109","doi-asserted-by":"publisher","first-page":"2301515","DOI":"10.1002\/adhm.202301515","volume":"12","author":"AG Hamilton","year":"2023","unstructured":"Hamilton AG, Swingle KL, Joseph RA, et al. Ionizable lipid nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T cell Engineering. Adv Healthc Mater. 2023;12(30):2301515.","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"536_CR110","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130\u201344.","journal-title":"J Clin Invest"},{"issue":"4","key":"536_CR111","doi-asserted-by":"publisher","first-page":"e008429","DOI":"10.1136\/jitc-2023-008429","volume":"12","author":"W Ouyang","year":"2024","unstructured":"Ouyang W, Jin SW, Xu N, et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer. 2024;12(4):e008429.","journal-title":"J Immunother Cancer"},{"issue":"23","key":"536_CR112","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez ER, Chang DK, Sun J, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341\u201355.","journal-title":"Oncotarget"},{"issue":"22","key":"536_CR113","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","volume":"23","author":"S Li","year":"2017","unstructured":"Li S, Siriwon N, Zhang X, et al. Enhanced Cancer Immunotherapy by chimeric Antigen receptor\u2013modified T cells Engineered to secrete checkpoint inhibitors. Clin Cancer Res. 2017;23(22):6982\u201392.","journal-title":"Clin Cancer Res"},{"key":"536_CR114","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omto.2021.03.014","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Yang S, Li S, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy. Mol Therapy Oncolytics. 2021;21:144\u201357.","journal-title":"Mol Therapy Oncolytics"},{"issue":"1","key":"536_CR115","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Zhu T, Jiang G, et al. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer. Mol Cancer. 2023;22(1):131.","journal-title":"Mol Cancer"},{"issue":"1","key":"536_CR116","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijrobp.2009.04.018","volume":"77","author":"SH Son","year":"2010","unstructured":"Son SH, Choi BO, Kim GW, et al. Primary Radiation Therapy in patients with localized Orbital marginal zone B-Cell lymphoma of Mucosa-Associated Lymphoid tissue (MALT lymphoma). Int J Radiat Oncol Biol Phys. 2010;77(1):86\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"536_CR117","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7(1):258.","journal-title":"Signal Transduct Target Ther"},{"key":"536_CR118","doi-asserted-by":"publisher","first-page":"648655","DOI":"10.3389\/fonc.2021.648655","volume":"11","author":"PQ Fang","year":"2021","unstructured":"Fang PQ, Gunther JR, Wu SY, et al. Radiation and CAR T-cell therapy in Lymphoma: future frontiers and potential opportunities for Synergy. Front Oncol. 2021;11:648655.","journal-title":"Front Oncol"},{"issue":"3","key":"536_CR119","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13277-012-0329-z","volume":"33","author":"T Lindgren","year":"2012","unstructured":"Lindgren T, Stigbrand T, Riklund K, et al. Gene expression profiling in MOLT-4 cells during gamma-radiation-induced apoptosis. Tumor Biology. 2012;33(3):689\u2013700.","journal-title":"Tumor Biology"},{"issue":"4","key":"536_CR120","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.freeradbiomed.2007.10.048","volume":"44","author":"D Gupta","year":"2008","unstructured":"Gupta D, Crosby ME, Almasan A, et al. Regulation of CD20 expression by radiation-induced changes in intracellular redox status. Free Radic Biol Med. 2008;44(4):614\u201323.","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"536_CR121","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","volume":"26","author":"C DeSelm","year":"2018","unstructured":"DeSelm C, Palomba ML, Yahalom J, et al. Low-dose Radiation Conditioning enables CAR T cells to mitigate Antigen escape. Mol Ther. 2018;26(11):2542\u201352.","journal-title":"Mol Ther"},{"issue":"1","key":"536_CR122","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10(1):134.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"536_CR123","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","volume":"13","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Wang Y, Xu P, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020;13(1):27.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"536_CR124","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu QF, Xu LP, et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk Acute Lymphoblastic Leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467\u201376.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"536_CR125","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956\u201362.","journal-title":"Blood"},{"issue":"12","key":"536_CR126","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for Acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273\u201383.","journal-title":"J Clin Oncol"},{"issue":"1","key":"536_CR127","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"X Zhang","year":"2021","unstructured":"Zhang X, Chen J, Han MZ, et al. The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.","journal-title":"J Hematol Oncol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-024-00536-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:05:42Z","timestamp":1721293542000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-024-00536-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1186\/s40164-024-00536-0","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}